Harmine has no lung-protective effects in a canine model of lung ischemia-reperfusion injury

doi:10.3969/j.issn.2095-4344.2014.36.012

Abstract

Abstract:

BACKGROUND: Inflammatory cell activation and the generation of oxygen free radicals are important factors of lung ischemia-reperfusion injury. Adding the drugs with anti-inflammation and antioxidant effects into the lung preservation solution used, can improve the protection fluid, and play a crucial role in the study of lung ischemia-reperfusion injury and protection of the function of transplanted lung.
OBJECTIVE: To discussion the effect of harmine in canine model of pulmonary ischemia-reperfusion injury.
METHODS: Twelve healthy hybrid dogs were randomly divided into two groups, with six rats in each group. A canine model of lung ischemia-reperfusion injury was established, and the protecting liquid was perfused with the clockwise irrigation method. Control group: low potassium dextran protective fluid; experimental group: low potassium dextran + harmine protective fluid. After 2 hours of ischemia, the left lung circulation was recovered. The left lung tissue and blood samples were collected from two groups of animal models after reperfusion, and their cytokines levels and the lung wet/dry weight ratio were detected and calculated. Bronchoalveolar lavage fluid was collected to observe the pathological indicators. The main pulmonary artery pressure, left and right pulmonary artery pressure were recorded by continuous monitoring.
RESULTS AND CONCLUSION: There were no statistically significant differences in the interleukin-17, tumor necrosis factor α and endothelin 1 content in the left lung tissue and the blood between the two groups at 2 and 4 hours after reperfusion (P > 0.05). After 4 hours of reperfusion in both groups, the neutrophil number, the
number of lymphocytes, alveolar edema index, and vascular wall damage in bronchoalveolar lavage fluid showed no statistically significant differences (P > 0.05). Through the analysis of variance, the main pulmonary artery pressure, left pulmonary artery pressure and right pulmonary artery pressure also had no statistical significance between the two groups (P > 0.05). By the analysis of cytokines, pathological indicators, lung wet/dry weight ratio, and pulmonary arterial pressure, harmine has no significant lung protection effect in canine model of lung ischemia-reperfusion injury.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: models, animal, reperfusion injury, lung, dextrans, harmine

CLC Number:

R318

Zhang Hao, Qi Hai, Li Yuan-ming, Chen Jia-hua. Harmine has no lung-protective effects in a canine model of lung ischemia-reperfusion injury[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(36): 5805-5812.

Figures/Tables 6

References

[1] Forgiarini LA Jr, Grün G, Kretzmann NA,et al.When is injury potentially reversible in a lung ischemia-reperfusion model. J Surg Res. 2013;179(1):168-174.
[2] Venuta F, Diso D, Anile M, et al. Evolving techniques and perspectives in lung transplantation.Transplant Proc. 2005; 37(6):2682-2683.
[3] Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury.Transplant Rev (Orlando). 2009; 23(1):1-10.
[4] Christie JD, Edwards LB, Aurora P,et al.The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009.J Heart Lung Transplant. 2009; 28(10):1031-1049.
[5] Grichnik KP, D'Amico TA.Acute lung injury and acute respiratory distress syndrome after pulmonary resection.Semin Cardiothorac Vasc Anesth. 2004;8(4): 317-334.
[6] Ng CS, Wan S, Yim AP,et al. Pulmonary dysfunction after cardiac surgery.Chest. 2002;121(4):1269-1277.
[7] Cour M, Gomez L, Mewton N,et al.Postconditioning: from the bench to bedside.J Cardiovasc Pharmacol Ther. 2011;16(2): 117-130.
[8] Steen S, Sjöberg T, Massa G,et al.Safe pulmonary preservation for 12 hours with low-potassium-dextran solution.Ann Thorac Surg. 1993;55(2):434-440.
[9] Kelly RF, Murar J, Hong Z,et al. Low potassium dextran lung preservation solution reduces reactive oxygen species production.Ann Thorac Surg. 2003;75(6):1705- 1710.
[10] Bando T, Albes JM, Fehrenbach H,et al. Influence of the potassium concentration on functional and structural preservation of the lung: where is the optimum.J Heart Lung Transplant. 1998;17(7):715-724.
[11] Müller C, Bittmann I, Hatz R,et al.Improvement of lung preservation -- from experiment to clinical practice.Eur Surg Res. 2002;34(1-2):77-82.
[12] Strüber M, Hohlfeld JM, Fraund S,et al.Low-potassium dextran solution ameliorates reperfusion injury of the lung and protects surfactant function.J Thorac Cardiovasc Surg. 2000; 120(3):566-572.
[13] Gámez P, Córdoba M, Millán I,et al. Improvements in lung preservation: 3 years' experience with a low-potassium dextran solution.Arch Bronconeumol. 2005;41(1):16-19.
[14] Strüber M, Wilhelmi M, Harringer W,et al. Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation.Eur J Cardiothorac Surg. 2001; 19(2):190-194.
[15] Chu Y, Wu YC, Chou YC,et al.Endothelium-dependent relaxation of canine pulmonary artery after prolonged lung graft preservation in University of Wisconsin solution: role of L-arginine supplementation.J Heart Lung Transplant. 2004; 23(5):592-598.
[16] Khan FA, Maalik A, Iqbal Z,et al.Recent pharmacological developments in β-carboline alkaloid "harmaline".Eur J Pharmacol. 2013;721(1-3):391-394.
[17] Cao R, Peng W, Wang Z, et al.beta-Carboline alkaloids: biochemical and pharmacological functions.Curr Med Chem. 2007;14(4):479-500.
[18] Berrougui H, Martín-Cordero C, Khalil A,et al.Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta.Pharmacol Res. 2006; 54(2):150-157.
[19] Moura DJ, Richter MF, Boeira JM,et al.Antioxidant properties of beta-carboline alkaloids are related to their antimutagenic and antigenotoxic activities.Mutagenesis. 2007;22(4): 293-302.
[20] Chen YF, Kuo PC, Chan HH,et al.β-carboline alkaloids from Stellaria dichotoma var. lanceolata and their anti-inflammatory activity.J Nat Prod. 2010;73(12):1993-1998.
[21] Yamazaki Y, Kawano Y.Inhibitory effects of herbal alkaloids on the tumor necrosis factor-α and nitric oxide production in lipopolysaccharide-stimulated RAW264 macrophages.Chem Pharm Bull (Tokyo). 2011;59(3):388-391.
[22] Bi W, Bi Y, Xue P,et al.Novel β-carboline-tripeptide conjugates attenuate mesenteric ischemia/reperfusion injury in the rat.Eur J Med Chem. 2011;46(6):2441-2452.
[23] Murata T, Nakazawa H, Mori I,et al.Reperfusion after a two-hour period of pulmonary artery occlusion causes pulmonary necrosis.Am Rev Respir Dis. 1992;146(4):1048- 1053.
[24] McCord JM.Oxygen-derived free radicals in postischemic tissue injury.N Engl J Med. 1985;312(3):159-163.
[25] Grichnik KP, D'Amico TA.Acute lung injury and acute respiratory distress syndrome after pulmonary resection.Semin Cardiothorac Vasc Anesth. 2004;8(4):317-334.
[26] Klass O, Fischer UM, Antonyan A,et al.Pneumocyte apoptosis induction during cardiopulmonary bypass: effective prevention by radical scavenging using N-acetylcysteine.J Invest Surg. 2007;20(6):349-356.
[27] Page AB, Owen CR, Kumar R,et al.Persistent eIF2alpha(P) is colocalized with cytoplasmic cytochrome c in vulnerable hippocampal neurons after 4 hours of reperfusion following 10-minute complete brain ischemia.Acta Neuropathol. 2003; 106(1):8-16.
[28] Tapuria N, Kumar Y, Habib MM,et al.Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury--a review.J Surg Res. 2008;150(2):304-330.
[29] de Perrot M, Liu M, Waddell TK, et al. Ischemia-reperfusion-induced lung injury.Am J Respir Crit Care Med. 2003;167(4):490-511.
[30] Snell GI, Levvey BJ, Zheng L,et al.Interleukin-17 and airway inflammation: a longitudinal airway biopsy study after lung transplantation.J Heart Lung Transplant. 2007; 26(7):669-674.
[31] Miyamoto M, Prause O, Sjöstrand M, et al.Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways.J Immunol. 2003;170(9):4665-4672.
[32] Yoshida S, Haque A, Mizobuchi T,et al.Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants.Am J Transplant. 2006;6(4):724-735.
[33] Sharma AK, LaPar DJ, Zhao Y, et al.Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury.Am J Respir Crit Care Med. 2011 ;183(11):1539-1549.
[34] Vanaudenaerde BM, Dupont LJ, Wuyts WA, et al.The role of interleukin-17 during acute rejection after lung transplantation.Eur Respir J. 2006;27(4):779-787.
[35] Loong CC, Hsieh HG, Lui WY, et al.Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection.J Pathol. 2002;197(3):322-332.
[36] Lindén A, Laan M, Anderson GP.Neutrophils, interleukin-17A and lung disease.Eur Respir J. 2005;25(1):159-172.
[37] Yao Z, Painter SL, Fanslow WC,et al.Human IL-17: a novel cytokine derived from T cells.J Immunol. 1995;155(12): 5483-5486.
[38] Laan M, Cui ZH, Hoshino H, et al.Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways.J Immunol. 1999;162(4):2347-2352.
[39] Rahman MS, Yang J, Shan LY,et al.IL-17R activation of human airway smooth muscle cells induces CXCL-8 production via a transcriptional-dependent mechanism.Clin Immunol. 2005;115(3):268-276.
[40] Albanesi C, Cavani A, Girolomoni G.IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.J Immunol. 1999;162(1):494-502.
[41] Ye P, Rodriguez FH, Kanaly S,et al.Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.J Exp Med. 2001;194(4): 519-527.
[42] Jones CE, Chan K.Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells.Am J Respir Cell Mol Biol. 2002;26(6):748-753.
[43] Laan M, Palmberg L, Larsson K,et al.Free, soluble interleukin-17 protein during severe inflammation in human airways.Eur Respir J. 2002;19(3):534-537.
[44] Molet S, Hamid Q, Davoine F,et al.IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines.J Allergy Clin Immunol. 2001;108(3):430-438.
[45] Khimenko PL, Bagby GJ, Fuseler J,et al.Tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lungs.J Appl Physiol (1985). 1998;85(6):2005-2011.
[46] Cerami A.Inflammatory cytokines.Clin Immunol Immunopathol. 1992;62(1 Pt 2):S3-10.
[47] Yoshizumi M, Kurihara H, Morita T,et al. Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells.Biochem Biophys Res Commun. 1990; 166(1):324-329.
[48] Yamashita M, Schmid RA, Ando K,et al.Nitroprusside ameliorates lung allograft reperfusion injury.Ann Thorac Surg. 1996;62(3):791-796.
[49] Jahaniani F, Ebrahimi SA, Rahbar-Roshandel N,et al. Xanthomicrol is the main cytotoxic component of Dracocephalum kotschyii and a potential anti-cancer agent.Phytochemistry. 2005;66(13):1581-1592.
[50] Schwarz MJ, Houghton PJ, Rose S,et al.Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism.Pharmacol Biochem Behav. 2003;75(3): 627-633.
[51] Farouk L, Laroubi A, Aboufatima R,et al.Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: possible mechanisms involved.J Ethnopharmacol. 2008; 115(3):449-454.
[52] Astulla A, Zaima K, Matsuno Y.Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities.J Nat Med. 2008;62(4):470-472.
[53] Arshad N, Neubauer C, Hasnain S,et al.Peganum harmala can minimize Escherichia coli infection in poultry, but long-term feeding may induce side effects.Poult Sci. 2008; 87(2):240-249.
[54] Zheng XY, Zhang ZJ, Chou GX,et al.Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of Peganum nigellastrum Bunge by an in vitro TLC- bioautographic assay.Arch Pharm Res. 2009;32(9):1245- 1251.
[55] Toledo-Pereyra LH, Hau T, Simmons RL,et al.Lung preservation techniques.Ann Thorac Surg. 1977;23(5): 487-494.
[56] Hausen B, Ramsamooj R, Hewitt CW,et al.The importance of static lung inflation during organ storage: the impact of varying ischemic intervals in a double lung rat transplantation model.Transplantation. 1996;62(12):1720-1725.
[57] Kofidis T, Strüber M, Warnecke G,et al.Antegrade versus retrograde perfusion of the donor lung: impact on the early reperfusion phase.Transpl Int. 2003;16(11):801-805.
[58] Roe DW, Fehrenbacher JW, Niemeier MR,et al.Lung preservation: pulmonary flush route affects bronchial mucosal temperature and expression of IFN-gamma and Gro in regional lymph nodes.Am J Transplant. 2005;5(5):995-1001.